Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scalp Psoriasis
Conditions
Scalp Psoriasis
Trial Timeline
Oct 22, 2018 → Mar 15, 2019
NCT ID
NCT03880357About Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension is a phase 1 stage product being developed by Sun Pharmaceutical for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03880357. Target conditions include Scalp Psoriasis.
What happened to similar drugs?
0 of 6 similar drugs in Scalp Psoriasis were approved
Approved (0) Terminated (0) Active (6)
🔄PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03880357 | Phase 1 | Completed |
Competing Products
7 competing products in Scalp Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DSXS topical product | Sun Pharmaceutical | Phase 2 | 35 |
| PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension | Sun Pharmaceutical | Phase 3 | 40 |
| DSXS + Placebo | Sun Pharmaceutical | Phase 3 | 40 |
| DSXS topical + Vehicle topical | Sun Pharmaceutical | Phase 3 | 40 |
| Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo | Glenmark Pharmaceuticals | Phase 3 | 40 |
| Secukinumab 300 mg + Placebo | Novartis | Phase 3 | 40 |
| Roflumilast Foam 0.3% + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 34 |